Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2024 | CLADRINA: MS patient stability in the transition from natalizumab to cladribine

Ferhan Qureshi, SVP – Biomarker R&D, Octave Bioscience, Menlo Park, CA, discusses the CLADRINA study (NCT04178005), which uses the multiple sclerosis disease activity (MSDA) test to assess if patients with mutliple sclerosis (MS) remain stable when transitioning from natalizumab to cladribine. The trial compared baseline MSDA scores to scores at different time points up to 12 months after the transition and found that patients mainly remained stable. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Ferhan Qureshi is an employee of Octave Bioscience.